ERBB2 and colorectal carcinoma: Well-established predictive biomarkers include HER2 overexpression which predicts breast cancer response to anti-HER2 therapies like trastuzumab and KRAS, NRAS and BRAF mutations which predict resistance to Epithelial Growth Factor Receptor (EGFR) inhibitors in CRC (Jørgensen et al., 2016).